Nanobodies

A Global Strategic Business Report

MCP37476

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

7148

EXECUTIVE POOL

5850

PRICE

817

EXPERT INPUTS

34

COMPANIES

315

DATA TABLES

379

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Nanobodies Market to Reach US$1.5 Billion by 2030

The global market for Nanobodies estimated at US$561.0 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 18.0% over the analysis period 2024-2030. Mono-Specific Type, one of the segments analyzed in the report, is expected to record a 19.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Multi-Specific Type segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$152.8 Million While China is Forecast to Grow at 24.0% CAGR

The Nanobodies market in the U.S. is estimated at US$152.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$342.4 Million by the year 2030 trailing a CAGR of 24.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 16.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global Nanobodies Market - Key Trends & Drivers Summarized

Why Are Nanobodies Gaining Momentum in Therapeutics and Diagnostics?

Nanobodies, also known as single-domain antibodies, are a unique class of antibody fragments derived from camelid species. Unlike conventional antibodies, nanobodies are small, stable, and can bind to hidden or difficult-to-reach epitopes. Their compact size allows better tissue penetration, rapid clearance from the bloodstream, and ease of manufacturing. These properties make them highly attractive for applications in oncology, autoimmune diseases, infectious disease treatment, and diagnostic imaging.

Their structural simplicity also enables rapid engineering into multi-specific formats or fusion proteins. Nanobodies can be delivered through non-traditional routes such as inhalation or topical application, offering alternatives to injectable biologics. With pharmaceutical developers increasingly seeking targeted, fast-acting, and cost-effective biologics, nanobodies are positioned as next-generation tools in both therapeutic development and in vivo diagnostics.

How Is Innovation in Design and Delivery Expanding Nanobody Potential?

Advances in protein engineering and phage display libraries are improving nanobody discovery and affinity optimization. Researchers can now generate synthetic nanobody libraries without direct reliance on camelid immunization, accelerating development timelines. Nanobodies are being designed for multivalent formats, which enhance binding strength or engage multiple targets simultaneously—especially relevant in cancer immunotherapy and viral neutralization.

In drug delivery, nanobodies are being fused with toxins, cytokines, or radionuclides to selectively target diseased cells. Their ability to be expressed in microbial systems like E. coli or yeast reduces production costs compared to full-length monoclonal antibodies. Nanobody-drug conjugates, nanobody-based CAR-T therapies, and bispecific formats are also under active development. These advances allow tailored delivery of therapeutic payloads while minimizing systemic exposure and immune-related toxicity.

Which Applications Are Driving Demand Across Research and Clinical Settings?

In diagnostics, nanobodies are widely used in biosensors, immunoassays, and molecular imaging tools. Their stability under extreme conditions makes them suitable for point-of-care testing and field-based detection systems. In imaging, nanobody-based PET tracers enable real-time visualization of tumors, inflammation, or infectious sites with higher resolution and faster clearance compared to conventional antibodies.

Therapeutically, nanobodies are being investigated for inflammatory conditions, cancers, neurodegenerative diseases, and viral infections including COVID-19. In oncology, nanobody-drug conjugates and immune checkpoint inhibitors are showing promise in early-phase clinical trials. In neurology, their ability to cross the blood-brain barrier is under evaluation for targeted delivery to amyloid plaques or misfolded proteins in diseases like Alzheimer’s and Parkinson’s. Veterinary medicine and agricultural biotechnology are also exploring nanobodies for disease control and detection.

Growth in the Nanobodies Market Is Driven by Several Factors…

Growth in the nanobodies market is driven by several factors. Rising demand for targeted biologics and precision diagnostics encourages development of compact and high-affinity binding molecules. Advances in synthetic biology and display technologies accelerate nanobody discovery and screening. Cost-effective microbial expression systems support scalable production. Expanding clinical pipeline and regulatory support for biologics enhance commercial viability. Increased investment in oncology, neurodegeneration, and infectious disease research creates new application opportunities. Partnerships between biotech firms, academic labs, and pharmaceutical companies further support product development, licensing, and market expansion.

SCOPE OF STUDY

The report analyzes the Nanobodies market by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Mono-Specific Type, Multi-Specific Type); Application (Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application, Bone Disorders Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Research Laboratories End-Use, Other End-Uses).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

AbCellera Biologics Inc.; Abiocenter; Alpaca Nanobodies Inc.; Amgen Inc.; BIOCYTOGEN Group; Bio-Rad Laboratories; Boehringer Ingelheim GmbH; Capralogics Inc.; Creative Biolabs; Cusabio; GenScript Biotech Corporation; Merck KGaA; Morphosys AG (Ablynx tech); NanoTag Biotechnologies GmbH; Novartis AG; Proteintech Group, Inc.; PREGENE; QVQ Holding BV; Sanofi (Ablynx); Thermo Fisher Scientific; Yiteng Pharmaceutical

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

World Market Trajectories

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Nanobodies – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 34 Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Demand for Targeted and Versatile Biotherapeutics Drives Interest in Nanobody-Based Drug Development

Superior Stability and Smaller Molecular Size of Nanobodies Throws Spotlight on Their Use in Hard-to-Reach Targets

Advancements in Immunotherapy and Oncology Research Propel Adoption of Nanobody-Based Modalities

Expansion of Bispecific and Multivalent Therapeutics Supports Use of Nanobodies in Complex Drug Design

Growing Research Activity in Autoimmune and Inflammatory Diseases Enhances Scope for Nanobody Applications

Increased Use of Nanobodies in Diagnostic Imaging and Molecular Tracers Strengthens Demand in Precision Medicine

OEM Collaborations With Academic Institutions Accelerate Innovation in Rare and Orphan Disease Therapeutics

Favorable Pharmacokinetics and Reduced Immunogenicity Drive Preference Over Conventional Antibodies

Emerging Interest in Inhalable and Topical Drug Delivery Formats Fuels Development of Nanobody-Based Treatments

Growth in CNS and Blood-Brain Barrier Research Encourages Nanobody Use for Neurological Conditions

Vaccine Development and Viral Neutralization Studies Highlight Role of Nanobodies in Infectious Disease Management

4. GLOBAL MARKET PERSPECTIVE

World Nanobodies Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

World Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Nanobodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Mono-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Mono-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Mono-Specific Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Multi-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Multi-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Multi-Specific Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Respiratory Syncytial Virus Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Respiratory Syncytial Virus Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Systemic Lupus Erythematosus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Systemic Lupus Erythematosus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Systemic Lupus Erythematosus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Psoriasis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Psoriasis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Psoriasis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Bone Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Bone Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Bone Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Research Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

USA 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

USA Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

USA 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

USA Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

USA 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Canada 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Canada 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Canada 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

JAPAN

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Japan 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Japan 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Japan 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

CHINA

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

China 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

China Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

China 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

China Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

China 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

EUROPE

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Europe Historic Review for Nanobodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Europe 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Europe 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Europe 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Europe 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

FRANCE

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

France 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

France Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

France 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

France Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

France 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

GERMANY

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Germany 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Germany 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Germany 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Italy 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Italy 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Italy 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

UNITED KINGDOM

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

UK 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

UK Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

UK 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

UK Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

UK 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

SPAIN

Spain Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Spain 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Spain 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Spain 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

RUSSIA

Russia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Russia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Russia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Russia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Europe 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Europe 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Europe 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

ASIA-PACIFIC

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Nanobodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Asia-Pacific 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Asia-Pacific 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Asia-Pacific 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Asia-Pacific 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

AUSTRALIA

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)

Australia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Australia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Australia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Australia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

INDIA

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)

India Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

India Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

India 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

India Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

India Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

India 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

India Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

India Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

India 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

SOUTH KOREA

South Korea Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

South Korea 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

South Korea 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

South Korea 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Asia-Pacific 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Asia-Pacific 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Asia-Pacific 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

LATIN AMERICA

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)

Latin America Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Latin America Historic Review for Nanobodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Latin America 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Latin America 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Latin America 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Latin America 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

ARGENTINA

Argentina Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Argentina 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Argentina 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Argentina 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

BRAZIL

Brazil Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Brazil 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Brazil 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Brazil 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

MEXICO

Mexico Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Mexico 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Mexico 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Mexico 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

REST OF LATIN AMERICA

Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Latin America 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Latin America 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Latin America 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

MIDDLE EAST

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)

Middle East Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Middle East Historic Review for Nanobodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Middle East 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Middle East 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Middle East 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Middle East 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IRAN

Iran Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Iran 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Iran 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Iran 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

ISRAEL

Israel Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Israel 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Israel 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Israel 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

SAUDI ARABIA

Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Saudi Arabia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Saudi Arabia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Saudi Arabia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

UNITED ARAB EMIRATES

UAE Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

UAE 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

UAE 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

UAE 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

REST OF MIDDLE EAST

Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Middle East 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Middle East 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Rest of Middle East 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

AFRICA

Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

Africa Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Africa 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Africa 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR

Africa 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll